Last reviewed · How we verify
Miebo
At a glance
| Generic name | Miebo |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Approved indications
- Dry eye disease
Common side effects
- Blurred vision
- Conjunctival redness
Serious adverse events
- Hypersensitivity
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear (PHASE4)
- A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease (PHASE4)
- A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy (PHASE4)
- A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months. (PHASE4)
- Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Miebo CI brief — competitive landscape report
- Miebo updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI